Fiche centre
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan — Italy
Essais liés5clinical trials
VilleMilanlocalisation
PaysItalylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07678775
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Tacabrutideg | Cancer | Phase 3 | NCT06846671 | CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| IMPACT STREAM — Master Framework For Relapse or Refractory Acute Myeloid Leukemia | Cancer | À vérifier | NCT06459024 | IMPACT STREAM — Master Framework For Relapse or Refractory Acute Myeloid Leukemia | RECRUITING |
| BBP-418 (ribitol) | Myopathies | Phase 3 | NCT07678775 | Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9 | ACTIVE_NOT_RECRUITING |
| BIA 28-6156 | Parkinson | À vérifier | NCT07522606 | Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study | NO_LONGER_AVAILABLE |